Case Discussion and Literature Review: Cancer Immunotherapy, Severe Immune-Related Adverse Events, Multi-Inflammatory Syndrome, and Severe Acute Respiratory Syndrome Coronavirus 2

• Main Authors: Dristhi Ragoonanan, Sajad J. Khazal, Rodrigo Mejia, Linette Ewing, Jean-Bernard Durand, Lara Bashoura, Jean Tayar, Natalie Dailey Garnes, Demetrios Petropoulos, Priti Tewari, Micah Bhatti, Ali Haider Ahmad, Jose Cortes, Shehla Razvi, Katrina McBeth, Rita Swinford, Basirat Shoberu, Waseem Waseemuddin, Linda Chi, Jonathan B. Gill, Wafik Zaky, Najat Daw, Cristina Gutierrez, Welela Tereffe, Partow Kebriaei, Katayoun Rezvani, Elizabeth J. Shpall, Richard E. Champlin, Kris M. Mahadeo
• Format: Article
• Language: English
• Published: Frontiers Media S.A. 2021-02-01
• Series: Frontiers in Oncology
• Subjects: SARS-CoV-2; cancer immunotherapy; MIS-C; MIS-A; COVID-19
• Online Access: https://www.frontiersin.org/articles/10.3389/fonc.2021.625707/full
• ISSN: 2234-943X

Pediatric, adolescent and young adult (AYA) patients receiving novel cancer immunotherapies may develop associated toxicities with overlapping signs and symptoms that are not always easily distinguished from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection/clinical sequelae. We describe 2 diagnostically challenging cases of SARS-CoV-2 and Multi-Inflammatory Syndrome-Adult (MIS-A), in patients with a history of acute lymphoblastic leukemia following cellular therapy administration and review evolving characterization of both the natural course of SARS-CoV-2 infection and toxicities experienced in younger cancer immunotherapy patients. Vigilant monitoring for unique presentations and epidemiologic surveillance to promptly detect changes in incidence of either condition may be warranted.